Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Dec;103(12):5985-5988.
doi: 10.1007/s00277-024-06127-7. Epub 2024 Nov 30.

Pyoderma gangrenosum-like neutrophilic dermatosis as an adverse effect of menin-KMT2A inhibitor therapy for acute myeloid leukaemia

Urbain Tauveron-Jalenques  1 , Khadim Sarr  2 , Romain Guièze  2   3 , Chloé Giordano  4 , Jacques Rouanet  4   5 , Sandrine Hayette  6   7 , Carole Chevenet  8 , Maël Heiblig  9 , Aurélie Ravinet  2
Affiliations
Case Reports

Pyoderma gangrenosum-like neutrophilic dermatosis as an adverse effect of menin-KMT2A inhibitor therapy for acute myeloid leukaemia

Urbain Tauveron-Jalenques et al. Ann Hematol. 2024 Dec.

Abstract

Menin-KMT2A inhibitors (MENi) are a novel class of small-molecule inhibitors in development in KMT2Ar and NPM1m acute myeloid leukaemias (AML) and a notorious cause of differentiation syndrome (DS). A 71 years old woman received the MENi revumenib (REV) for relapsed/refractory NPM1m AML. After 2 weeks of treatment, she developed fever and a violaceous inflammatory cutaneous lesion of the right cheek, revealing REV induced pyoderma gangrenosum (PG)-like neutrophilic dermatosis (ND). Isolated reports of all-trans retinoic acid induced DS-related ND have been published. However, to our knowledge, this is the first report ever of MENi induced PG-like ND and cutaneous involvement of DS. This report highlights the fact that ND such as PG, as a manifestation of DS, are a possibly severe adverse effect of MENi.

Keywords: Acute myeloid leukaemia; Differentiation syndrome; Menin inhibitor; Neutrophilic dermatosis; Pyoderma gangrenosum; Revumenib.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: This study is in accordance with the ethical standards of our institution and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent: Informed consent was obtained from the patient. Competing interests: The authors declare no competing interests.

References

    1. Patro R, Duggal G, Love MI et al (2017) Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 14(4):417–419. https://doi.org/10.1038/nmeth.4197 - DOI - PubMed - PMC
    1. Issa GC, Aldoss I, DiPersio J et al (2023) The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 615(7954):920–924. https://doi.org/10.1038/s41586-023-05812-3 - DOI - PubMed - PMC
    1. Jabbour E, Searle E, Abdul-Hay M et al (2023) A first-in-human phase 1 study of the Menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 alterations. Blood 142(Supplement 1):57 Oral abstract presentation, 65th ASH annual meeting and exposition, San Diego, California, 2023 - DOI
    1. Issa GC, Aldoss I, Thirman MJ et al Menin Inhibition with Revumenib for KMT2A-Rearranged relapsed or refractory Acute Leukemia (AUGMENT-101). J Clin Oncol 2024 Aug 9:JCO2400826. https://doi.org/10.1200/JCO.24.00826
    1. Frankel SR, Eardley A, Lauwers G et al (1992) The retinoic acid syndrome in acute promyelocytic leukemia. Ann Intern Med 117(4):292–296. https://doi.org/10.7326/0003-4819-117-4-292 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources